Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 301

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 301
---
 validation for CogniMIR ® •the terms and timing of any future collaboration, licensing, or other arrangements that DiamiR may establish; •the outcome, timing, and cost of meeting regulatory requirements; •the cost of obtaining, maintaining, defending, and enforcing intellectual property rights, including patent rights; •the effect of competing technological and market developments; •market acceptance of CogniMIR ®if DiamiR meets regulatory requirements for its commercialization; and •the extent to which DiamiR acquires, licenses, or invests in businesses, products or technologies. Until DiamiR can generate a sufficient amount of revenue from CogniMIR ®and related services and products, if ever, DiamiR expects to finance future cash needs through public or private equity offerings, debt financings or grants. Additional funds may not be available when needed on terms that are acceptable to DiamiR, or at all. If adequate funds are not available, DiamiR may be required to delay, reduce the scope of or eliminate our commercialization efforts. To the extent that DiamiR raises additional funds by issuing shares of common stock, its shareholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that DiamiR raises additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to its technologies or its product candidates or grant licenses on terms that may not be favorable to DiamiR. DiamiR may seek to access the public or private capital markets whenever conditions are favorable, even if DiamiR does not have an immediate need for additional capital at that time. 175 DiamiR does not expect CogniMIR ®to be commercially available with reimbursement in place before fiscal 2027, if at all. DiamiR will need to raise substantial additional capital to complete the development and commercialization of CogniMIR ®. Because successful development of CogniMIR ®is uncertain, DiamiR is unable to estimate the actual funds required to complete research and development and commercialize CogniMIR ®. DiamiR also will need to raise substantial additional capital to complete the development and commercialization of other products currently in development. Going Concern DiamiR has a limited operating history and incurred net losses of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and $493,710 in the nine